Since ATX (which generates the potent LPA mitogen via its potent lyso-PLD activity) is elevated in ccRCC [13, 41] and has been shown to mediate chemotherapeutic resistance to sunitinib [14], this may be another mechanism underlying resistance to mTOR inhibitors. This evidence concerns the gene GPLD1 and nonpapillary renal cell carcinoma.